Open AccessPalifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
Author(s) -
Ricardo Spielberger,
Patrick J. Stiff,
William Bensinger,
Teresa Gentile,
Daniel J. Weisdorf,
Tarun Kewalramani,
Thomas C. Shea,
Saul Yanovich,
Keith Hansen,
Stephen J. Noga,
John M. McCarty,
C. Frederick LeMaistre,
Eric Sung,
Bruce R. Blazar,
D. Elhardt,
Mon-Gy Chen,
Christos Emmanouilides
Publication year - 2004
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa040125
Subject(s) - mucositis , medicine , radiation therapy , complication , chemotherapy , stomatitis , dermatology , oncology , gastroenterology
Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom